Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aquestive Therapeutics Inc
(NQ:
AQST
)
3.090
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aquestive Therapeutics Inc
< Previous
1
2
3
Next >
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
May 31, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 02, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
April 26, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
April 20, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
April 18, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
March 29, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
March 07, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 01, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
February 22, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 21, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
January 06, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
December 22, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
November 29, 2022
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
November 15, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
November 09, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 01, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
October 27, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
October 24, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
October 19, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
October 11, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ:AQST Investor Notice: Investigation over Potential Wrongdoing at Aquestive Therapeutics, Inc.
September 29, 2022
San Diego, CA -- (SBWIRE) -- 09/29/2022 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation on over potential breaches of fiduciary duties.
Via
SBWire
Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets
September 28, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ:AQST Investor Notice: Update in Lawsuit Against Aquestive Therapeutics, Inc. Announced
August 25, 2022
San Diego, CA -- (SBWIRE) -- 08/25/2022 -- The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST).
Via
SBWire
NASDAQ:AQST Shareholder Notice: Investigation over Potential Wrongdoing at Aquestive Therapeutics, Inc.
March 09, 2022
San Diego, CA -- (SBWIRE) -- 03/09/2022 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shareholder Notice: Update in Lawsuit
January 19, 2022
San Diego, CA -- (SBWIRE) -- 01/19/2022 -- An update was announced in the lawsuit that is pending for certain investors in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST).
Via
SBWire
SHAREHOLDER ALERT: Robbins LLP Investigates Aquestive Therapeutics, Inc. (AQST) on Behalf of Shareholders
December 21, 2021
From
Robbins LLP
Via
Business Wire
NASDAQ:AQST Long Term Investor Notice: Investigation over Possible Wrongdoing at Aquestive Therapeutics, Inc.
May 24, 2021
San Diego, CA -- (SBWIRE) -- 05/24/2021 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties.
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 30, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
AQST Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 30, 2021
April 30, 2021
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 29, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.